Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Imago BioSciences, Inc.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021
From Imago BioSciences, Inc.
Via Business Wire
Tickers IMGO
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
From Imago BioSciences, Inc.
Via Business Wire
Tickers IMGO
Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates
From Imago BioSciences, Inc.
Via Business Wire
Tickers IMGO
Imago BioSciences, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
From Imago BioSciences, Inc.
Via Business Wire
Tickers IMGO
Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
From Imago BioSciences, Inc.
Via Business Wire
Tickers IMGO
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
From Imago BioSciences, Inc.
Via Business Wire
Tickers IMGO
Imago BioSciences, Inc. Announces Proposed Initial Public Offering of Common Stock
From Imago BioSciences, Inc.
Via Business Wire
Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress
From Imago BioSciences, Inc.
Via Business Wire
Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical Officer
From Imago BioSciences, Inc.
Via Business Wire
Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress
From Imago BioSciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.